Unleashing the Full Potential of Proteasome Inhibition to Treat Disease
About Us
IpiNovyx Bio is developing best-in-class proteasome inhibitors to treat cancer, autoimmune and inflammatory diseases. Backed by cutting-edge research from Weill Cornell Medicine and the Hospital for Special Surgery, we are advancing a new class of highly selective and reversible immunoproteasome inhibitors to effectively treat disease.
Innovative Science Driving Our Pipeline
Our proprietary technology platform focuses on discovering and developing novel, reversible and selective inhibitors of the proteasome to create safer, more effective treatments for patients suffering from cancer and autoimmune disease. Discover how our science is paving the way for the next generation of proteasome-targeting therapies.
Investing in the Future of Healthcare
With strong backing from leading investors and institutions, and a lead program anticipated to enter the clinic in 2026, IpiNovyx is poised for significant growth. Join our mission to transform treatment for cancer and autoimmune disease.
